Delft takes majority interest in Rogan

Delft Instruments has increased its interest in Rogan Medical Systems from 35% to 52%. Rogan, which markets its PACS software worldwide under the name HyperPACS, will continue to trade as a separate Delft operating company. Rogan already collaborates with two other Delft companies: Nucletron for radiotherapy and thorax imaging and Oldelft Benelux for equipment distribution and maintenance.